The havoc of the corona pandemic is still not over worldwide. Cases of coronavirus are continuously coming in many parts of the world including America, Europe. Under this, the US has now decided to introduce booster doses of the vaccine to all its adult population.
US vaccine company Pfizer on Tuesday asked US regulators to allow booster doses of the vaccine for people 18 years of age or older. This step has been taken by America because holidays and travel are about to start there. In such a situation, with the increasing crowd of people, the risk of spreading coronavirus can also increase. In view of this, America has taken this decision. Earlier in September, in the US, older people and especially those with weakened immunity vulnerable to the virus were allowed to apply booster doses of the vaccine.
Europe Lags Behind America In Vaccination
According to a report by American TV channel NBC, Europe lags far behind America in terms of vaccination. There are 67% of the total population of America who have received at least one dose of the vaccine. The highest rate in Europe is in Portugal, where 87% of the population has had a dose. Now it is likely that many countries of Europe will also intensify the campaign to apply booster doses. Meanwhile, the challenge remains how to improve the situation in European countries that have low vaccination rates.
American pharmaceutical company Pfizer announced that it has entered into an agreement to make its oral antiviral Covid-19 vaccine more affordable in poor countries. On behalf of the company, it has been said that if this drug passes the trials and regulatory approvals, then it will be available to a large part of the world, especially in low and middle-income countries, at a very low cost.
Read Also:-Is An Organic Vitamin C Serum The Best Carrier Of Vitamin C?
American pharmaceutical company Pfizer announced that it has entered into an agreement to make its oral antiviral Covid-19 vaccine more affordable in poor countries. On behalf of the company, it has been said that if this drug passes the trials and regulatory approvals, then it will be available to a large part of the world, especially in low and middle-income countries, at a very low cost.
In a statement, Pfizer said it would license the anti-virus drug to the United Nations-backed public health organization Medicines Patent Pool (MPP), which would allow ‘generic’ drug makers to produce it. According to the company, this will enable the use of this drug in 95 countries of the world, where about 53 percent of the world’s population lives. Last month, the company had made a similar deal with American company Merck & Co. After the deal, this drug is known to be taken with HIV medicine.
This is most important for more than 4 billion people, said Esteban Baron, head of policy at the Medicines Patent Pool. We will be able to provide access to a drug that appears to be effective and has just been developed. In a statement Tuesday, Pfizer said it would license the antiviral pill to the Geneva-based Medicines Patent Pool, which would allow generic drug companies to produce the pill for use in 95 countries, which make up about 53% of the world’s population.
He speculated that other drugmakers would be able to begin production of the pill within months, but acknowledged that the settlement would not please everyone. We try to strike a delicate balance between the interests of the company and that of ordinary producers, Baron said. Most importantly, there are public health needs in low and middle-income countries.
